GE Healthcare
Imaging, monitoring, and healthcare IT solutions
Digital Product Manager - MR and Women's Health, Third Party Applications
Relocation assistance is provided.
About the job
- A bachelor's degree in marketing, business, engineering, healthcare, or another related field.
- Experience working in product development.
- Strong analytical and process skills.
- Strong project management skills.
- Ability to take initiative and drive deliverables to closure.
- Ability to work effectively in a collaborative, matrixed, and customer-focused environment.
- Excellent communication, stakeholder management, and organizational skills.
- Own and manage the Magnetic Resonance and Women's Health third-party post-processing, advanced visualization, and digital application portfolio.
- Drive lifecycle management for third-party applications, including new product introductions, upgrades, renewals, and end-of-life planning.
- Support development and execution of product roadmaps with modality product managers and digital product leaders.
- Evaluate emerging market opportunities and third-party capabilities to identify portfolio expansion opportunities.
- Assess partner technologies and solutions for alignment with customer needs, business strategy, and product roadmaps.
- Serve as the primary business interface for third-party post-processing and visualization suppliers.
- Build and maintain strategic relationships with external partners.
- Lead supplier onboarding with engineering, sourcing, legal, cybersecurity, and quality teams.
- Coordinate supplier release schedules, deliverables, product updates, and roadmap alignment.
- Manage supplier communications, including change requests, technical notifications, product updates, and escalation management.
- Ensure partner commitments, timelines, and business objectives are achieved.
- Collaborate with product managers to develop business cases for new third-party offerings and investment opportunities.
- Partner with commercial, finance, and marketing teams to establish pricing, packaging, subscription models, and commercialization strategies.
- Ensure third-party solutions are available within catalogs, configurators, and price books.
- Support go-to-market strategies and launch plans for new offerings.
- Monitor portfolio performance, adoption, revenue growth, and customer feedback to inform future investments.
- Establish and lead operating mechanisms with internal teams and external suppliers.
- Coordinate cross-functional deliverables and release timing across product management, engineering, sourcing, quality, and commercial operations.
- Drive issue resolution and facilitate decision-making across multiple stakeholders.
- Develop launch plans and supporting collateral with marketing teams and third-party suppliers.
- Coordinate product positioning, value propositions, customer-facing materials, and sales enablement content.
- Support field teams with product training, competitive insights, and customer engagement activities.
- Ensure successful product introductions and market adoption.
- Coordinate third-party suppliers, fulfillment teams, and internal stakeholders.
- Ensure accurate product configuration, ordering, entitlement management, and fulfillment processes.
- Track product releases, software updates, and regulatory or compliance-related notifications.
- Implement scalable operating mechanisms and governance processes to improve portfolio management efficiency.
- An MSc or master's degree in marketing, engineering, science, business administration, or another related field.
- At least 5 years of experience in product marketing, product development, or a related field within the medical device industry.
- Product management or marketing expertise, including market trends and analysis, new product introduction processes, product roadmap development, product lifecycle management, and healthcare product, industry, or technical acumen.
- Experience working globally.
- Experience working within the Scaled Agile Framework process.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Orders rose 11% in Q2 2026, lifting backlog to a record $23.9 billion.
- Vivid Explorer, Advanced, and Focus launched at ESC 2026 with CE Mark approval.
- Invenia ABUS Prime and StreamVue won FDA clearance, targeting dense-breast screening demand.
What critics are saying
- Patient Care Solutions revenue fell 13.5% in Q2 2026, and management reviews a sale.
- CFO Jay Saccaro departs in 2026, leaving George Newcomb interim during execution risk.
- If PCS stays weak through 2027, GE HealthCare loses cash and strategic focus.
What makes GE Healthcare unique
- GE HealthCare’s installed base spans 2 billion annual scans and 54,000 employees.
- Photonova Spectra gained CE mark on August 31, 2026, after FDA and Japan.
- CareIntellect for Operations launched September 16, 2026, forecasting bottlenecks 72 hours ahead.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.
GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.